• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Glenmark Pharma gets ANDA tentative approval for Dabigatran Etexilate Capsules

expresspharmaDecember 22, 2020

Tag: Glenmark , Dabigatran Etexilate Capsules , ANDA , Pradaxa Capsules , FDA

Glenmark Pharmaceuticals has received tentative approval by the United States Food & Drug Administration (US FDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg, the generic version of Pradaxa Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim Pharmaceuticals.

According to IQVIA sales data for the 12 month period ending October 2020, the Pradaxa Capsules, 75 mg, 110 mg, and 150 mg market achieved annual sales of approximately $550.9 million.

Glenmark’s current portfolio consists of 166 products authorised for distribution in the US marketplace and 45 ANDA’s pending approval with the US FDA.

Previous:Takeda to divest select assets in China to Hasten Biopharmaceutic for $322 mn

Next:Sosei Heptares and GSK sign collaboration and license pact targeting GI immune disorders

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Glenmark Pharma gets ANDA tentative approval for Dabigatran Etexilate Capsules | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Standard single unit

Standard single unit
Nabumetone (FDA)

Nabumetone (FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
Clean Room Manufacturer GMP Standard Modular Turnkey Cleanroom Project Supplier for Medical Hospital

Clean Room Manufacturer GMP Standard Modular Turnkey Cleanroom Project Supplier for Medical Hospital
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
toc standard method

toc standard method
Etoposide( FDA)

Etoposide( FDA)
High Quality Good Price Thymalfasin fandachem Thymosin α1 Thymosin Alpha 1 CAS 62304-98-7 for Gym Bo

High Quality Good Price Thymalfasin fandachem Thymosin α1 Thymosin Alpha 1 CAS 62304-98-7 for Gym Bo
Ferric Pyrophosphate Food Grade Manufacture USP Bp FCC Standard

Ferric Pyrophosphate Food Grade Manufacture USP Bp FCC Standard
LGJ-30F Standard Type Experimental Freeze Dryer

LGJ-30F Standard Type Experimental Freeze Dryer

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service